Granzyme B PET Imaging Drug as a Predictor of Immunotherapy Response to Checkpoint Inhibitors

Lymphoma Clinical Trial

Official title:

First in Human Safety of [68Ga]-NOTA-hGZP- PET Imaging in Subjects Receiving Checkpoint Inhibitor Immunotherapy

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04169321
• Other study ID #: 2019-hGZP-101.12
• Status: Recruiting
• Phase: Phase 1
• Start date: June 16, 2020
• Est. completion date: February 28, 2026

Study information

• Verified date: August 2023
• Source: Cytosite Biopharma Inc.
• Contact: Colin G Miller, PhD
• Phone: 2679182806
• Email: cmiller[@]cytositebio.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

First in Human Safety of [68Ga]-NOTA-hGZP PET Imaging in subjects with cancer undergoing treatment with a checkpoint inhibitor either as a monotherapy of in combination I-O therapy

Description:

This is a first in human research study (Phase I clinical trial) to test the safety and effectiveness of a new radioactive PET imaging drug and biomarker [68Ga]-NOTA-hGZP. It is a multi-center, open label, non-randomized, two dose study to evaluate the safety of [68Ga]-NOTA-hGZP and the ability to predict the clinical response to checkpoint inhibitor therapy within 2 cycles of treatment.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 30
• Est. completion date: February 28, 2026
• Est. primary completion date: December 30, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Subjects 18 years of age and older.

2. Subjects with proven metastatic cancer that is going to be treated with one or more checkpoint inhibitors under the licensed indications for the cancer type. Checkpoint inhibitors include PD-1, PD-L1, CTLA-4 and LAG-3 inhibitors.

3. Subjects must have at least one lesion = 15 mm in diameter or with two lesions both = 15mm in diameter, when an optional biopsy is planned. Lesion measurements are taken from a diagnostic quality CT or MR image.

4. ECOG performance status = 2 (Karnofsky = 60%)

5. Life expectancy of greater than 6 months.

6. Males and females willing to use adequate contraception prior to study and during study participation.

7. If female, not of childbearing potential or negative pregnancy test prior to radiotracer injection.

8. Willing and able to understand and sign a written informed consent document.

9. Willing and able to undergo all study procedures.

10. Cohort 3 only: have archival lesion tissue available within 90 days of enrollment either from biopsy or surgery.

Exclusion Criteria:

1. Participants for whom adverse events due to agents administered more than 4 weeks earlier have not resolved to Grade 1 or less.

2. Has not received nor is expected to receive an investigational compound within 90 days prior to [68Ga]-NOTA-hGZP PET imaging. This includes checkpoint inhibitors that are not approved by the US FDA for the indications in this protocol.

3. Subjects who have received a prior checkpoint inhibitor.

4. Any acute or chronic inflammatory disease or medical conditions that in the investigator's opinion may interfere with the study procedures or the interpretation of the study results such as infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia.

5. Known brain metastases.

6. History of allergic reactions to compounds of similar chemical or biologic composition to [68Ga]-NOTA-hGZP or pembrolizumab.

7. If female, nursing.

8. Current treatment with systemic steroids, or immunosuppressive agents. Participants with a condition requiring systemic treatment with either corticosteroids (< 10 mg daily prednisone equivalent) inhaled or topical steroids, and adrenal replacement steroid doses > 10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease.

9. Subjects who have exclusion criteria that would prevent them from receiving a CT scan.

10. Laboratory values

1. Leukocytes < 3000/mcL

2. Absolute neutrophil count < 1500 mcL

3. Platelets < 100,000 mCL

4. Total bilirubin > 1.5 x ULN

5. AST/ALT > 2.5 x ULN

6. Albumin < 2 g/dL

7. Alkaline phosphatase > 2.5 ULN

8. eGRF eGFR < 45 mL/min/1.73 m2 Patients who are stable but have values outside the specified ranges may be included with approval of the study medical monitor.

Related Conditions & MeSH terms

• Lymphoma
• Solid Tumor, Unspecified, Adult

Intervention

Drug:
• Single Arm
[68Ga]-NOTA-hGZP is a PET imaging agent.

Locations

Country	Name	City	State
Taiwan	Chang-Gung Memorial Hospital	Taoyuan City	Guishan
United States	University of Alabama at Birmingham	Birmingham	Alabama
United States	Massachusetts General Hospital	Boston	Massachusetts

Sponsors (4)

Lead Sponsor	Collaborator
Cytosite Biopharma Inc.	Chang Gung Memorial Hospital, Massachusetts General Hospital, University of Alabama at Birmingham

Countries where clinical trial is conducted

United States,  Taiwan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of participants with clinically meaningful changes in physical examination findings, vital signs or blood chemistry	Clinically significant changes from baseline in physical examination findings; Clinically significant changes from baseline to follow-up analysis in systolic and diastolic blood pressure (mmHg); Clinically significant changes from baseline to follow-up analysis in heart rate (beats per minute); Clinically significant changes in respiration rate.; Clinically significant changes from baseline to follow-up analysis in blood chemistry for: Leukocytes (/mcL),; Absolute neutrophil count (mcL); Platelets (/mcL); Total bilirubin (mg/d); AST/ALT (unitless); Albumin (g/dL); Alkaline phosphatase (IU/L); eGRF (mL/min/1.73 m2)	up to 4 to 6 hours post-injection
Primary	Number of participants with changes in ECG	Clinically significant changes from baseline to follow-up analysis in ECG change in QT (ms) Quantification of [68Ga]-NOTA-hGZP PET accumulation at tumor site in subjects after treatment with checkpoint inhibitor therapy as determined by region of interest analysis (SUVmean).	up to 4 to 6 hours post-injection
Primary	Number of participants with treatment-related Adverse Events (AEs)	The absolute number of participants with AEs according to CTCAE 5.0	Between time of injection and 3 days post injection
Secondary	Evaluation of the accumulation of [68Ga]-NOTA-hGZP in tumor foci in participants receiving checkpoint inhibitor therapy (absolute number of avid lesions per subject)	Identification by the central reader of the number of avid lesions observed in each subject and the number of subjects with avid lesions seen on the PET images	up to one-hour post injection
Secondary	Quantification of accumulation of [68Ga]-NOTA-hGZP in tumor foci in participants receiving checkpoint inhibitor therapy.	To be determined by region of interest analysis the mean standardized uptake value (SUVmean) (SUV does not have any units)	up to one-hour post injection
Secondary	Evaluate the correlation of [68Ga]-NOTA-hGZP accumulation in tumor foci to 6-month outcome.	Compare quantified [68Ga]-NOTA-hGZP uptake to participant treatment response in individual lesions as assessed at 6-month clinical follow-up and/or CT assessments.; The number of lesions that were avid and the lesions that showed a decrease in size compared to those which increased in size.	6 months
Secondary	Correlate uptake of [68Ga]-NOTA-hGZP tracer and granzyme B expression as assessed on optional excisional biopsy when available (melanoma only).	Compare granzyme B protein quantification from biopsied tissue to the [68Ga]-NOTA-hGZP PET uptake acquired at the same location.	up to one-hour post injection